The vast majority of cellular fatty acids have chain lengths between 14 and 18 carbon atoms. As well as this, a small proportion (0.5 to 3% in wild-type yeast) of VLCFA with 20 or more carbon atoms are characteristic components of all eucaryotic membranes (
21,
30,
92,
176). Yeast VLCFAs have chain lengths of 24 to 26 carbon atoms and are usually attached by amide likages to the sphingosine backbone of sphingolipids (for a review, see reference
27). In spite of their very low cellular concentrations, VLCFAs are, for reasons which are not fully understood, essential for cell viability (
65,
123). The VLCFA-synthesizing enzyme systems are designated fatty acid elongases rather than as FASs. Nevertheless, mechanistically they may represent FASs that use long-chain fatty acyl-CoA rather than acetyl-CoA as a primer. Similar to FASs, elongases use malonyl-CoA and NADPH as extender and reducing substrates, respectively (
30,
114). FASs and elongases are considered to catalyze homologous reaction sequences utilizing a functionally homologous set of component enzymes. As a possible exception and mechanistic pecularity, however, it remains to be demonstrated whether, like FASs, elongases use enzyme-bound phosphopantetheine for the malonyl-CoA dependent condensation reaction. So far, evidence is missing for the presence of an additional functional yet unassigned pantetheinylated protein in yeast. As is known from the chalcon and stilben synthases of plants, pantetheine-independent malonyl-CoA condensations have evolved in some systems independently of the usual FAS and PKS systems (
72). In agreement with this view and with the characteristics of chalcon synthesis, yeast elongase is insensitive to the FAS ketoacyl synthase inhibitor cerulenin (
114). As a further difference from most FAS systems, elongases are not soluble cytoplasmic enzymes but are localized in the microsomal membrane fraction. Even though the purification and molecular characterization of a distinct elongase system has not been achieved so far, available data suggest that elongases have a nonaggregated molecular structure consisting of physically independent enzyme entities. By genetic inactivation and subsequent isolation, two putative yeast elongase genes,
YBR159w and
TSC13, have recently been identified. They encode, respectively, an elongase-specific β-ketoacyl reductase and an enoyl reductase (
10,
47,
65,
114). Using a specific in vitro elongase assay, at least three different elongase systems have been identified in yeast. They may be differentiated according to their differential primer usage and product specificities: -elongase I extends C
12 to C
16 primers to C
16 to C
18 fatty acids, elongase II converts C
16 to C
18 acyl-CoAs to C
22 fatty acids, and elongase III synthesizes C
24 to C
26 fatty acids from C
18-CoA (
114). Elongase I has no function in VLCFA synthesis but probably serves to extend medium-chain-length fatty acids which eventually result from pre-early-chain termination of cytoplasmic FASs. For each elongation system, one of the three closely related yeast genes,
ELO1,
ELO2, and
ELO3, fulfills an essential although presently still elusive function (
30,
103,
114,
162). Consequently,
elo1,
elo2, and
elo3 mutants are specifically defective in one of the elongase I to III. Elongases II and III share some of their components, such as β-ketoacyl reductase and enoyl reductase (
114,
47). The presence of redundant elongases or, alternatively, the lethality of their functional loss prevented the isolation of yeast elongase mutants for a long time. In contrast to the fatty acid requirement of yeast FAS mutants, elongase-defective mutants cannot be supplemented by the elongase reaction products, i.e., external VLCFAs. Recently, however,
elo1 mutants have been isolated based on the failure of
elo1/fas double mutants to elongate and, consequently, to use 12:0 as a fatty acid supplement (
30,
162). In contrast,
ELO1-positive
fas mutants readily convert 12:0 to the essential C
14 to C
18 acids. The enoyl reductase and ketoacyl reductase components of elongases II and III were identified on the basis of the abnormal sphingolipid composition of a respective mutant (
TSC13) (
65) and by an extensive database search with subsequent biochemical characterization of candidate mutants (
YBR159w) (
47,
114). Elongase II and III mutants are viable even though they are VLCFA negative in vitro (
114). In contrast to these in vitro characteristics, VLCFA synthesis is reduced but not absent in vivo (
47,
114). The VLCFA level in the
ybr159wΔ mutant was 20 to 30% of that in the wild type. Thus, an additional elongation system appears to be functional in intact yeast cells. This system is obviously inactivated by addition of the FAS inhibitor cerulenin to the growth medium or, alternatively, by mutational inactivation of cytoplasmic FAS. Both methods induce synthetic lethality in the elongase mutants (
114). This data may indicate that yeast FAS participates not only in de novo fatty acid synthesis but also in fatty acid elongation. In contrast to the structurally related FAS of mycobacteria, which synthesizes both C
16 to C
18 and C
24 to C
26 fatty acids, a bimodal product pattern of yeast FAS is not evident in vitro. It may nevertheless be speculated that in vivo, a fraction of cellular FAS is associated with the microsomal membrane and thereby engages in VLCFA synthesis. The general potential of yeast FAS to synthesize VLCFAs has been demonstrated in
Schizosaccharomyces pombe. Here, certain
FAS2 mutants unaffected in de novo FAS activity are reported to produce a considerable amount of C
30 fatty acid (
185). As a consequence, these mutants exhibited distinct alterations in cell shape and physiology (
118). Remarkably, a membrane-bound FAS variant was identified in
Drosophila melanogaster that was distinctly different from the homologous cytoplasmic FAS (
45). The possible involvement of this variant in VLCFA synthesis remains to be demonstrated.